Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (91-100 of 236) with videos related to

Pageof 24
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2005
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivoChristian Blank, Ian Brown, Aalok K Kacha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejectionIan E Brown, Christian Blank, Justin Kline, et al.
European Journal of Immunology|September 30, 2003
T cell development and function in CrkL-deficient miceAmy C Peterson, Reinhard E Marks, Patrick E Fields, et al.
The Oncologist|January 3, 2023
Association Between Rheumatic Autoantibodies and Immune-Related Adverse EventsKristen Mathias, Sherin Rouhani, Daniel Olson, et al.
Trends in Immunology|November 6, 2012
Type I interferon response and innate immune sensing of cancerMercedes B Fuertes, Seng-Ryong Woo, Byron Burnett, et al.
Journal of Leukocyte Biology|July 2, 2003
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccinesKatharina Tschoep, Thomas C Manning, Helena Harlin, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanomaRobin Reschke, Jovian Yu, Blake Flood, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacySantiago Acero-Bedoya, Emily F Higgs, Anna C Martinez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 2010
Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylationGregory Driessens, Yan Zheng, Frederick Locke, et al.
Immunological Reviews|July 30, 2019
STING pathway agonism as a cancer therapeuticBlake A Flood, Emily F Higgs, Shuyin Li, et al.
Pageof 24

Showing results (91-100 of 236) with videos related to

Sort By:
Pageof 24
Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2005
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivoChristian Blank, Ian Brown, Aalok K Kacha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejectionIan E Brown, Christian Blank, Justin Kline, et al.
European Journal of Immunology|September 30, 2003
T cell development and function in CrkL-deficient miceAmy C Peterson, Reinhard E Marks, Patrick E Fields, et al.
The Oncologist|January 3, 2023
Association Between Rheumatic Autoantibodies and Immune-Related Adverse EventsKristen Mathias, Sherin Rouhani, Daniel Olson, et al.
Trends in Immunology|November 6, 2012
Type I interferon response and innate immune sensing of cancerMercedes B Fuertes, Seng-Ryong Woo, Byron Burnett, et al.
Journal of Leukocyte Biology|July 2, 2003
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccinesKatharina Tschoep, Thomas C Manning, Helena Harlin, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanomaRobin Reschke, Jovian Yu, Blake Flood, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacySantiago Acero-Bedoya, Emily F Higgs, Anna C Martinez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 2010
Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylationGregory Driessens, Yan Zheng, Frederick Locke, et al.
Immunological Reviews|July 30, 2019
STING pathway agonism as a cancer therapeuticBlake A Flood, Emily F Higgs, Shuyin Li, et al.
Pageof 24